Welcome to our dedicated page for Gilead Sciences news (Ticker: $GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Gilead Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Gilead Sciences's position in the market.
Rhea-AI Summary
Gilead Sciences and Arcus Biosciences announce promising results from the Phase 2 EDGE-Gastric study, showing encouraging overall response rate (ORR) and six-month progression-free survival (PFS) rate in patients with gastric, gastroesophageal junction, or esophageal adenocarcinoma. Domvanalimab plus zimberelimab and chemotherapy demonstrated an ORR of 80% in patients with PD-L1-high tumors and 46% in patients with PD-L1-low tumors. Six-month PFS rates were 93% and 68% for PD-L1-high and PD-L1-low tumors, respectively. Detailed results will be presented at the ASCO Monthly Plenary Series.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
-
Rhea-AI Summary
Gilead Sciences and Arcus Biosciences announce positive results from the Phase 2 EDGE-Gastric study, showing promising overall response rate (ORR) and six-month progression-free survival (PFS) rate. Domvanalimab plus zimberelimab and chemotherapy demonstrated an ORR of 80% in patients with PD-L1-high tumors and 46% in patients with PD-L1-low tumors. The six-month PFS rate was 93% for PD-L1-high tumors and 68% for PD-L1-low tumors. The regimen was well tolerated with a similar safety profile to anti-PD-1 plus chemotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
-
Rhea-AI Summary
Gilead Sciences announces new viral hepatitis data presented at AASLD The Liver Meeting®. Key findings include primary endpoint results from the Phase 2b MYR204 study evaluating Hepcludex® (bulevirtide) in combination with pegylated interferon alfa-2a (PegIFNα) in patients with chronic hepatitis delta virus (HDV), and an integrated analysis of Week 96 data from pivotal Phase 2b and Phase 3 studies evaluating the efficacy and safety of bulevirtide monotherapy. Long-term results from studies of Vemlidy® (tenofovir alafenamide, TAF) in chronic hepatitis B (HBV) will also be presented.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
Rhea-AI Summary
Gilead Sciences and Kite, a Gilead Company, will present 29 presentations at the 65th American Society of Hematology (ASH) Annual Meeting. Key presentations include three-year results from ZUMA-12 investigating CAR T-cell therapy, post-hoc analyses showing the curative intent of Yescarta, and real-world evidence studies for Tecartus. New clinical data from the Phase 1 study of CART-ddBCMA in patients with multiple myeloma will also be featured.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
-
Rhea-AI Summary
Gilead, a biopharmaceutical company, is committed to health equity and addressing the needs of communities with the greatest unmet needs. The company focuses on supporting and advocating for Black women and girls, who are disproportionately affected by disease. Gilead recently participated in the U.S. Conference on HIV/AIDS, where the theme was 'A Love Letter to Black Women'. Black women account for 54% of new HIV diagnoses among women aged 16 and older, despite comprising only 14% of the population. However, they are underrepresented in HIV clinical trials due to barriers like stigma, medical distrust, and limited access to trial study sites.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
-
Rhea-AI Summary
Kite, a Gilead Company, and Epicrispr Biotechnologies have entered into a research collaboration and license agreement to develop next-generation cancer cell therapies. Kite will gain access to Epic Bio's gene regulation platform to enhance CAR T-cell functionality. Epic Bio will receive upfront payment, milestone payments, and royalties on approved products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
Rhea-AI Summary
Gilead Sciences has been recognized as the top philanthropic funder of HIV-related programs for the second year in a row. The company distributed over 1,000 HIV-related grants worth nearly $240 million, making them the number one funder globally and in the U.S. Gilead was also recognized as the top funder in various categories, including support for BIPOC communities, transgender communities, and programs for gay men and sex workers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
-
Rhea-AI Summary
Gilead Sciences presents new data supporting Sunlenca as an important treatment option for adults with multi-drug resistant HIV. The data highlight the significance of lenacapavir as a person-centric therapy option and its potential to transform the future of coordinated HIV clinical care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
-
Rhea-AI Summary
Gilead Sciences presents new long-term real-world data from the BICSTaR study on the safety and efficacy of Biktarvy as a treatment for HIV
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
Rhea-AI Summary
Gilead Sciences has announced the launch of PURPOSE 5, the first Phase 2 clinical trial to evaluate lenacapavir as a long-acting HIV prevention option in Europe. The study aims to assess the persistence of lenacapavir compared to current pre-exposure prophylaxis (PrEP) options in people who may benefit from PrEP and are not currently taking it. The trial focuses on recruiting participants from groups disproportionately affected by HIV in France and the UK. Lenacapavir is a first-in-class HIV capsid inhibitor that can be administered as a twice-yearly subcutaneous injection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.01%
Tags
Gilead Sciences Inc
Nasdaq:GILD
GILD Rankings
GILD Stock Data
81.63B
1.24B
0.09%
88.37%
1.81%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
United States of America
FOSTER CITY
About GILD
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.